華安多個(gè)新品蛋白抗體上市助力抗擊新型冠狀病毒

部分實(shí)驗(yàn)數(shù)據(jù)

A.SDS-PAGE analysis of ACE2-hFC, ACE2-mFc and SARS-CoV-2 RBD-hFc.

B.ELISA Test of SARS-COV-2 RBD Fragment Fusion Protein Binding to ACE2-mFc Fusion Protein.

C.Representative standard curve for ACE2-hFC, ACE2-mFc and SARS-CoV-2 RBD-hFc protein ELISA.

Fig A,B,C: The binding activity of  anti-SARS-CoV-2 Nucleocapsid Protein antibody with SARS-CoV-2 Recombinant Nucleocapsid protein.The EC50 of  is 71.22 ng/ml (A, ER1902-39), 381.8 ng/ml 
(B, EM1902-20),  271.3 ng/ml (C, EM1902-21).
Fig A', B', C': Western blot analysis of anti-SARS-CoV-2 Nucleocapsid Protein antibody with N-terminal His tag-tagged SARS-CoV-2 Nucleocapsid protein (1) and inactivated native SARS-CoV-2 lysate (2) at 20ng. A', ER1902-39; B', EM1902-20; C', EM1902-21.

A.Western blot of anti-ACE2 antibody（ER1902-40) with human kidney tissue.

B、C.FACS of anti-ACE2 antibody（ER1902-40) with Vero cell and ACE2 transfected 293 cell.

D.Western blot analysis of ACE2 on different cell lysates using anti-ACE2 antibody (ET1611-58) at 1/1000 dilution.

Positive control:Lane 1: Human kidney;Lane 2: Human intestine;Lane 3,4: Hamster cells

E.Immunohistochemical analysis of paraffin-embedded human kidney tissue using anti-ACE2 antibody (ET1611-58).

更多產(chǎn)品詳情見(jiàn)華安生物官網(wǎng)